SLDB May 2024 22.500 call
| Previous close | 0.6400 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 22.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.6400 - 0.6400 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
GlobeNewswireSolid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid — — Company ends first quarter 2024 with approximately $206.1 million in cash and investments.Solid has anticipated cash runway into 2026 — CHARLESTOWN, Mass., May 15, 2024 (GLOBE NEWSWIRE)
- GlobeNewswire
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company’s lead SGT-003 program — CHARLESTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present an oral presentation and six posters and at the American Society of Gene and Cell Therapy (ASGCT) 2024 A
- GlobeNewswire
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 38,508 restricted stock units (“RSUs”) to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the applicable employee’s start date until the fourth anniversary of the applicable employee’s start date. Vesting of the
